vinorelbine tartrate / Generic mfg. - LARVOL DELTA

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China (ASH 2025) - P2 | "The DI-based regimens included DICd (C: cyclophosphamide; d: dexamethasone) plus vinorelbine (VDS), DId plus VDS, DId plus denosumab, DId plus venetoclax (VEN), DIPd (P: pomalidomide), DIR (R: lenalidomide), and DIRd plus VEN. Conclusion The DI-based regimen, as an initial treatment option for transplant-ineligible NDMM patients, demonstrates efficacy comparable to that observed in previous prospective randomized controlled trials (RCTs) (NCT03012880, NTR6297, ORR: 71–96%). This real-world study conducted in China further supports the promising efficacy and acceptable safety profile of the ixazomib plus daratumumab-based regimen as a first-line treatment for transplant-ineligible NDMM patients in routine clinical practice, including among elderly patients with multiple comorbidities."

Clinical • Real-world • Real-world evidence • Cardiovascular • CNS Disorders • Diabetes • Hematological Disorders • Hematological Malignancies • Hepatology • Hypertension • Metabolic Disorders • Multiple Myeloma • Nephrology • Renal Disease • Transplantation • Vascular Neurology

Orelabrutinib combined with R-CDOP regimen for first-line treatment of diffuse large B-cell lymphoma with high-risk CNS-IPI (ASH 2025) - P2 | "Patients received orelabrutinib combined with an R-CDOP regimen:orelabrutinib 150 mg orally once daily; rituximab 375 mg/m²; cyclophosphamide 750 mg/m²; liposomaldoxorubicin 30 mg/m²; vinorelbine 25 mg/m² on day 1; and prednisone 100 mg daily on days 1–5.Treatment was given in 21-day cycles for a total of six cycles. Median OSwas 38.1 months, 1- and 2-year OS rates were 93.8 % and 90.2 %, respectively.During the study, all patients experienced grade 1-2 adverse reactions, with grade 3-4 adverse reactionsoccurring in 67.6% (25/37). The most common grade 3-4 adverse events were neutropenia (59.5%),anemia (24.3%) and thrombocytopenia (16.2%).ConclusionIn treatment-naïve, high-risk CNS-IPI DLBCL, the orelabrutinib plus R-CDOP regimen achieves early, deep,and durable responses with low CNS relapse rates (0% at 1 year and 9.3% at 2 years), which aresignificantly lower than the relapse rates with MTX plus R-CHOP prophylaxis (12.4% at 2 years), and..."

Clinical • IO biomarker • B Cell Lymphoma • Cardiovascular • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • BCL2

Bispecific antibodies serve as a safe and effective bridging therapy prior to CD19 CAR T-cell therapy/combinational therapy of CD19 CAR-T cell and HDT/ASCT in patients with R/R DLBCL (ASH 2025) - "The median number ofprior treatment lines before bridging therapy was 2 (range 1-4).Bridging therapy consisted of glofitamab monotherapy (3 patients) or glofitamab combined withchemotherapy (GVM [gemcitabine, vinorelbine, mitoxantrone hydrochloride liposome] in 4patients; GemOx [gemcitabine, oxaliplatin] in 4 patients). These preliminary data suggest that BsAbs-containing bridging therapy prior toCD19-specific CAR-T therapy, either alone or combined with HDT/ASCT, is effective and safe inDLBCL. More detailed data will be presented at the conference."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • TP53

Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT Induces Durable Remissions in PD-(L)1 inhibitor-resistant Refractory/relapsed classical Hodgkin lymphoma: A single-center, long-term study (ASH 2025) - "Post-PD-(L)1 inhibitor failure options remainlimited, with brentuximab vedotin (BV) constrained by cost barriers in resource-limited settings.Autologous stem cell transplantation (ASCT) offers curative potential but requires salvage-sensitiveregimen (≥partial response, PR) pre-transplantation...All participants had PD-(L)1 inhibitor-refractory/relapsed or intolerantdisease, received four 21-day cycles of BeGEV re-induction therapy: bendamustine (90 mg/m² IV on days2–3), gemcitabine (800 mg/m² IV on days 1 and 4), and vinorelbine (1.5 mg/m² [max 2 mg] IV on day 1).Patients achieving ≥ PR underwent immediate ASCT with G-CSF-only mobilization and BEAM conditioning(BCNU 300 mg/m² day -7, etoposide 200 mg/m² days -6 to -3, cytarabine 200 mg/m² days -6 to -3,melphalan 140 mg/m² day -2)...Following ASCT, rapid hematopoietic recovery was observed, with median times toneutrophil engraftment and platelet engraftment of 11 days and 15 days,..."

Clinical • Alopecia • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Neutropenia • CD34

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study (ASH 2025) - P2 | "Background :Platinum-based salvage chemotherapy is the most widely used treatment approach for relapsed orrefractory aggressive non-Hodgkin lymphoma (R/R aNHL), with an objective response rate (ORR) of 42.0–63.5% and a complete response (CR) rate of 13.5-40.0%.We previously reported the efficacy and safety ofa novel non-platinum-based salvage regimen—GVM±R (mitoxantrone hydrochloride liposome [Lipo-MIT],gemcitabine, vinorelbine, with or without rituximab)—in R/R aNHL, demonstrating promising activity withan ORR of 66.7% and a CR rate of 50.0% (ESMO 2024, Abstract #833P). The GVM±CD20 regimen exhibited encouraging efficacy in R/R aNHLs, including refractory cases. Themost common treatment-related toxicities were hematologic adverse events, which were manageablewith supportive care but required close monitoring. The phase II trial is currently ongoing."

Clinical • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukopenia • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Pneumonia • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia

Tisotumab vedotin vs investigator's choice of chemotherapy as second- or third-line (2L/3L) treatment for Chinese patients (pts) with recurrent or metastatic cervical cancer (r/mCC) in innovaTV 301 (ESMO Asia 2025) - P3 | "This report presents the first analysis of efficacy and safety of TV in Chinese pts with r/mCC, based on data from both global and China extension portions within innovaTV 301. Eligible pts had r/mCC with disease progression following standard chemotherapy doublet ± bevacizumab ± anti-PD-(L)1 therapy, measurable disease per RECIST v1.1, and an ECOG performance status of 0-1. Pts were randomised 1:1 to receive TV monotherapy or investigator's choice of topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed... TV as 2L/3L treatment demonstrated clinically meaningful improvements in OS, PFS, and ORR vs chemotherapy, with a manageable safety profile, for Chinese pts with r/mCC."

Clinical • Metastases • Cervical Cancer • Oncology • Solid Tumor

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=192 | Recruiting | Sponsor: Sun Yat-sen University | Enrolling by invitation ➔ Recruiting

Enrollment status • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Docetaxel and Gemcitabine Modulate Cellular Effects and Long Non-Coding RNA Profiles in Non-Small Cell Lung Cancer. (PubMed, Int J Mol Sci) - "According to the European Society for Medical Oncology guidelines for non-oncogene-addicted metastatic non-small-cell lung cancer (NSCLC), patients with metastatic squamous-cell carcinoma (LUSC) or metastatic non-squamous NSCLC with performance status 2 and PD-L1 < 50% may receive single-agent chemotherapy with gemcitabine (GEM), docetaxel (DOC), or vinorelbine. Analysis of three key long non-coding RNAs (lncRNAs)-MALAT1, NEAT1, and HOTAIR-showed variable expression in the studied cell lines as a potential response to DOC and GEM treatment. Our findings indicate different cellular effects of GEM and DOC in NSCLC cell lines and provide an overview of how currently used chemotherapeutics may influence the expression of lncRNAs."

IO biomarker • Journal • Lung Adenocarcinoma • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • HOTAIR • MALAT1 • NEAT1 • PD-L1

Pemetrexed plus platinum outperforms other platinum-based adjuvant chemotherapy regimens for resected stage II-IIIA lung adenocarcinoma: an open-label, historical-control study. (PubMed, J Thorac Dis) - "In addition, we retrospectively collected the data from 209 patients recorded between January 2003 and December 2021 with pathologic stage II-IIIA lung adenocarcinoma who received radical surgery followed by adjuvant non-PEM (paclitaxel, gemcitabine and vinorelbine) plus platinum as historical control. Besides, AEs of all grades were reported more frequently in the non-PEM plus platinum group than in PEM based group, such as neutropenia (76.1% vs. 25.4%), anemia (48.3% vs. 8.5%) and thrombocytopenia (23.4% vs. 5.6%). This study showed that PEM plus platinum outperforms non-PEM plus platinum as an adjuvant chemotherapy regimen for resected stage II-IIIA lung adenocarcinoma and with better tolerability."

Journal • Hematological Disorders • Lung Adenocarcinoma • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia

Phase 2 feasibility study of adjuvant chemotherapy with cisplatin (CDDP) and TS-1, followed by alternate-day TS-1 maintenance therapy, in patients with completely resected pathological stage II-IIIA non-small cell lung cancer. (PubMed, J Thorac Dis) - "Among these regimens, cisplatin plus vinorelbine (CDDP + VNR) has been most frequently used in Japan and shown to improve survival, but it is associated with significant toxicity that often limits treatment completion...This phase 2 study suggests that adjuvant therapy with CDDP + TS-1 followed by TS-1 monotherapy administered on alternate days is a feasible and relatively well-tolerated treatment regimen for patients with completely resected stage II-III NSCLC. The completion rate of the full protocol, survival outcomes, and limited AEs support the potential use of this regimen as a viable alternative within platinum-based adjuvant chemotherapy strategies."

Journal • P2 data • Hematological Disorders • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Definitive Staging and Perioperative Treatment for Resectable Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC): A UK Perspective (ISPOR-EU 2025) - "Neoadjuvant and adjuvant therapies were widely used and well tolerated, contributing to high resection rates and good disease control in resectable NSCLC."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Economic Impact of Adverse Event Management in HR+/HER2− Metastatic Breast Cancer: A Comparative Analysis of Datopotamab deruxtecan and standard of care in the Brazilian Private Healthcare System (SABCS 2025) - " The therapeutic regimens analyzed in this study were derived from two pivotal clinical trials: TB01, which compared Dato-DXd with ICC: (capecitabine, eribulin, gemcitabine, vinorelbine), and TROPICS-022, which assessed sacituzumab govitecan (SG) versus ICC. This analysis identified differences in AE-related costs across treatment modalities, emphasizing the economic relevance of toxicity management in patients with HR+/HER2− metastatic breast cancer who have progressed on endocrine therapy and received at least one line of systemic treatment. Dato-DXd demonstrated lower expenditures associated with adverse event management compared to its respective ICC arm comparator. SG was associated with higher AE-related costs relative to its respective ICC arm comparator."

Adverse events • HEOR • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

TrasTUCAN: Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P2 | N=13 | Terminated | Sponsor: Spanish Breast Cancer Research Group | Trial completion date: Aug 2026 ➔ May 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Aug 2026 ➔ May 2025; The study was closed early due to safety concerns and an unfavorable benefit-risk balance. Unexpected high neutropenia rates required a costly sub-study, which was not feasible, forcing the sponsor to terminate the trial prematurely.

Trial completion date • Trial primary completion date • Trial termination • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

OptiTROP-Breast01: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov) - P3 | N=254 | Active, not recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Mar 2025 ➔ Jun 2027

Trial completion date • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA1 • BRCA2 • HER-2 • PGR

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Neutropenia • Pediatrics • Soft Tissue Sarcoma

Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2- advanced breast cancer after CDK4/6 inhibitor. (PubMed, Breast Cancer Res Treat) - "Administering after CDK4/6i and capecitabine, VNR-GEMQ2W regimen shows activity in HR + /HER2- ABC and a manageable safety profile. This regimen should be considered as a potential control arm in the design of future clinical trials targeting HR + /HER2- ABC."

Journal • Retrospective data • Alopecia • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Neutropenia • Oncology • Solid Tumor • CDK4 • HER-2

Metronomic Chemo-Endocrine Therapy with Fulvestrant and Polychemotherapy in Heavily Pretreated ER+ Breast Cancer Patients: A Single-Center Cohort Study" (SABCS 2025) - "Therefore, we have hypothesized that combining ER degrader with metronomic polychemotherapy can improve clinical outcomes in advanced, endocrine-resistant ER+ breast cancer patients.Material and The treatment (FulVEC) consisted of a combination of fulvestrant (500 mg i.m. on days 1, 14, and 28, and every 4 weeks thereafter) with a VEC regimen (vinorelbine 40 mg p.o. three times a week, capecitabine 500 mg p.o. three times a day, cyclophosphamide 50 mg p.o. once a day). Chemo-endocrine therapy (FulVEC) comprising fulvestrant and metronomic polychemotherapy demonstrated high activity in pretreated, endocrine-refractory breast cancer patients. The activity of the FulVEC regimen compares favorably to available novel anti-cancer strategies used after failure of endocrine therapies. One of the most critical aspects of this therapy, besides its antitumor activity and safety, is its cost, which is minimal compared to novel therapeutic options considered for this patient..."

Clinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor

Serial Functional and Genomic Analyses Illuminate Clonal Evolution in Metastatic NSCLC with 12-Year Survival. (PubMed, Curr Oncol) - "Molecular events included the emergence of a BRAF V600E mutation responsive to dabrafenib plus trametinib and the acquisition of an EGFR exon 19 deletion responsive to Osimertinib. EVA/PCD identified activity for targeted agents and revealed synergy for vinorelbine plus Osimertinib not predicted by genomic profiling, which provided additional response. This case highlights clonal evolution in NSCLC and illustrates how serial tissue analyses correlating phenotypic and genomic events can offer therapeutic interventions to provide long-term survival. The integration of functional and genomic profiling may improve personalized treatment in NSCLC by interrogating tumor heterogeneity and clonal evolution to inform rational therapeutic selection."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF • EGFR

Evolutionary Therapy for Rhabdomyosarcoma (clinicaltrials.gov) - P2 | N=12 | Active, not recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Recruiting ➔ Active, not recruiting | N=28 ➔ 12

Enrollment change • Enrollment closed • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor • FOXO1

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "Fuzuloparib, either as monotherapy or in combination with apatinib, provided statistically significant improvements in progression-free survival compared with chemotherapy in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations, presenting as new treatment options."

Clinical • Journal • P3 data • P3 data: top line • Breast Cancer • Cardiovascular • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hypertension • Oncology • Septic Shock • Solid Tumor • BRCA1 • BRCA2 • HER-2

Microtubule Inhibitors Induce Cross-Resistance to Osimertinib Through CaMKII Activation in EGFR-Mutated NSCLC. (PubMed, Cancer Sci) - "To model acquired resistance, PC-9 cells were exposed to vinorelbine or paclitaxel for 18 weeks-approximating the clinical duration of four adjuvant chemotherapy cycles-and subsequent drug sensitivity and signaling pathway alterations were assessed using cell viability assays, RNA sequencing, and immunoblotting. These findings suggest that CaMKII plays a critical role in EGFR-TKI resistance. This study underscores the importance of optimizing the timing of EGFR-TKI administration in the therapeutic sequence for EGFR-mutated NSCLC."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR • FZD7

A Case Report of Advanced Pulmonary Adenocarcinoma in a Dog Managed with Chemotherapy and Cytokine-Based Immunotherapy. (PubMed, Animals (Basel)) - "Treatment included vinorelbine-based chemotherapy and cytokine-based immunotherapy using interleukin (IL)-15, IL-12, IL-23, and selenium...The dog survived for 241 days, including 143 days after stage IV diagnosis, exceeding previously reported outcomes. Although NK cell function was not directly evaluated, these findings raise the possibility that cytokine-based NK cell immunotherapy, when combined with chemotherapy, could have contributed to disease control and prolonged survival in advanced canine pulmonary adenocarcinoma."

Journal • Lung Adenocarcinoma • Lung Cancer • Oncology • Pulmonary Disease • Solid Tumor • IL12A • IL23A

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov) - P3 | N=686 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Oct 2028 ➔ Jun 2028 | Trial primary completion date: Oct 2028 ➔ Jun 2028

Monotherapy • Trial completion date • Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor

Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme. (PubMed, Res Sq) - "The TTL was loaded with everolimus (TTL-E), vinorelbine (TTL-V), rapamycin (TTL-R), a combination (TTL-EV), or (TTL-RV). These formulations were tested in vivo on orthotopic GBM mice, combined with temozolomide and radiation...Mechanistic studies suggest TTL-EV plus radiation inhibits mTOR/MAPK pathways and sensitizes tumors to radiation. These findings offer a potential approach for improving GBM treatment."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Kaposi sarcoma in a female patient with multiple sclerosis: a case report. (PubMed, J Med Case Rep) - "This case expands the known clinical and demographic spectrum of Kaposi sarcoma, underscoring the importance of maintaining a high index of suspicion in atypical patient populations to prevent diagnostic delays. The co-occurrence of multiple sclerosis and Kaposi sarcoma underscores the importance of recognizing iatrogenic Kaposi sarcoma in patients receiving immunosuppressive therapy and calls for further research into the complex intersection of autoimmune disorders and iatrogenic treatment-related immune dysregulation in oncogenesis. This report underscores the importance of individualized, persistent therapeutic strategies in managing Kaposi sarcoma."

Journal • CNS Disorders • Epstein-Barr Virus Infections • Immunology • Kaposi Sarcoma • Multiple Sclerosis • Oncology • Sarcoma • Solid Tumor